Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Working Together to Advance Symptom Science in the Precision Era.

Dorsey SG, Griffioen MA, Renn CL, Cashion AK, Colloca L, Jackson-Cook CK, Gill J, Henderson W, Kim H, Joseph PV, Saligan L, Starkweather AR, Lyon D.

Nurs Res. 2019 Jan 10. doi: 10.1097/NNR.0000000000000339. [Epub ahead of print] No abstract available.

PMID:
30640195
2.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M.

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

3.

CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.

van Balen P, van Bergen CAM, van Luxemburg-Heijs SAP, de Klerk W, van Egmond EHM, Veld SAJ, Halkes CJM, Zwaginga JJ, Griffioen M, Jedema I, Falkenburg JHF.

Front Immunol. 2018 Dec 18;9:3016. doi: 10.3389/fimmu.2018.03016. eCollection 2018.

4.

Strengthening Inter- and Intraprofessional Collaborations to Advance Biobehavioral Symptom Science.

Starkweather AR, Colloca L, Dorsey SG, Griffioen M, Lyon D, Renn C.

J Nurs Scholarsh. 2019 Jan;51(1):9-16. doi: 10.1111/jnu.12456. Epub 2019 Jan 5.

PMID:
30614198
5.

Change in Pain Score after Administration of Analgesics for Lower Extremity Fracture Pain during Hospitalization.

Griffioen MA, Ziegler ML, O'Toole RV, Dorsey SG, Renn CL.

Pain Manag Nurs. 2018 Nov 12. pii: S1524-9042(18)30148-6. doi: 10.1016/j.pmn.2018.09.008. [Epub ahead of print]

PMID:
30442567
6.

How to quantify animal activity from radio-frequency identification (RFID) recordings.

Iserbyt A, Griffioen M, Borremans B, Eens M, Müller W.

Ecol Evol. 2018 Oct 2;8(20):10166-10174. doi: 10.1002/ece3.4491. eCollection 2018 Oct.

7.

Analgesics Administered for Pain During Hospitalization Following Lower Extremity Fracture: A Review of the Literature.

Griffioen MA, OʼBrien G.

J Trauma Nurs. 2018 Nov/Dec;25(6):360-365. doi: 10.1097/JTN.0000000000000402.

PMID:
30395036
8.

Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.

Loeff FC, Rijs K, van Egmond EHM, Zoutman WH, Qiao X, Kroes WGM, Veld SAJ, Griffioen M, Vermeer MH, Neefjes J, Frederik Falkenburg JH, Halkes CJM, Jedema I.

Am J Hematol. 2019 Jan;94(1):93-102. doi: 10.1002/ajh.25337. Epub 2018 Nov 25.

PMID:
30370942
9.

Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles.

Kremer AN, Zonneveld MI, Kremer AE, van der Meijden ED, Falkenburg JHF, Wauben MHM, Nolte-'t Hoen ENM, Griffioen M.

Eur J Immunol. 2018 Oct;48(10):1621-1631. doi: 10.1002/eji.201747152. Epub 2018 Aug 17.

10.

Evidence of splinting in low back pain? A systematic review of perturbation studies.

Prins MR, Griffioen M, Veeger TTJ, Kiers H, Meijer OG, van der Wurff P, Bruijn SM, van Dieën JH.

Eur Spine J. 2018 Jan;27(1):40-59. doi: 10.1007/s00586-017-5287-0. Epub 2017 Sep 12. Review.

PMID:
28900711
11.

Quantitative Sensory Testing and Current Perception Threshold Testing in Patients With Chronic Pain Following Lower Extremity Fracture.

Griffioen MA, Greenspan JD, Johantgen M, Von Rueden K, O'Toole RV, Dorsey SG, Renn CL.

Biol Res Nurs. 2018 Jan;20(1):16-24. doi: 10.1177/1099800417720725. Epub 2017 Jul 24.

12.

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH.

J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9.

13.

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.

Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.

14.

Acute Pain Characteristics in Patients with and without Chronic Pain following Lower Extremity Injury.

Griffioen MA, Greenspan JD, Johantgen M, Von Rueden K, O'Toole RV, Dorsey SG, Renn CL.

Pain Manag Nurs. 2017 Feb;18(1):33-41. doi: 10.1016/j.pmn.2016.10.002. Epub 2016 Dec 10.

15.

The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants.

van der Lee DI, Pont MJ, Falkenburg JH, Griffioen M.

PLoS One. 2016 Sep 12;11(9):e0162808. doi: 10.1371/journal.pone.0162808. eCollection 2016.

16.

ARTISAN PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding bias.

Koning MT, Kiełbasa SM, Boersma V, Buermans HPJ, van der Zeeuw SAJ, van Bergen CAM, Cleven AHG, Kluin PM, Griffioen M, Navarrete MA, Veelken H.

Br J Haematol. 2017 Sep;178(6):983-986. doi: 10.1111/bjh.14180. Epub 2016 Jun 15. No abstract available.

PMID:
27301611
17.

Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies.

Pont MJ, Honders MW, Kremer AN, van Kooten C, Out C, Hiemstra PS, de Boer HC, Jager MJ, Schmelzer E, Vries RG, Al Hinai AS, Kroes WG, Monajemi R, Goeman JJ, Böhringer S, Marijt WA, Falkenburg JH, Griffioen M.

PLoS One. 2016 May 12;11(5):e0155165. doi: 10.1371/journal.pone.0155165. eCollection 2016.

18.

The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.

Gram AM, Oosenbrug T, Lindenbergh MF, Büll C, Comvalius A, Dickson KJ, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MH, Tscharke DC, Hutt-Fletcher LM, Wiertz EJ, Hoeben RC, Ressing ME.

PLoS Pathog. 2016 Apr 14;12(4):e1005550. doi: 10.1371/journal.ppat.1005550. eCollection 2016 Apr.

19.

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.

Griffioen M, van Bergen CA, Falkenburg JH.

Front Immunol. 2016 Mar 15;7:100. doi: 10.3389/fimmu.2016.00100. eCollection 2016. Review.

20.

Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2.

Pont MJ, van der Lee DI, van der Meijden ED, van Bergen CA, Kester MG, Honders MW, Vermaat M, Eefting M, Marijt EW, Kielbasa SM, Hoen PA, Falkenburg JH, Griffioen M.

Clin Cancer Res. 2016 Aug 15;22(16):4185-96. doi: 10.1158/1078-0432.CCR-15-2307. Epub 2016 Mar 10.

21.

Methods for assessment of trunk stabilization, a systematic review.

Maaswinkel E, Griffioen M, Perez RS, van Dieën JH.

J Electromyogr Kinesiol. 2016 Feb;26:18-35. doi: 10.1016/j.jelekin.2015.12.010. Epub 2016 Jan 7. Review.

PMID:
26803526
22.

Trunk stabilization estimated using pseudorandom force perturbations, a reliability study.

Griffioen M, Maaswinkel E, Zuurmond WW, van Dieën JH, Perez RS.

J Biomech. 2016 Jan 25;49(2):244-51. doi: 10.1016/j.jbiomech.2015.12.007. Epub 2015 Dec 12.

23.

Characteristics of Patients with Lower Extremity Trauma with Improved and Not Improved Pain During Hospitalization: A Pilot Study.

Griffioen MA, Johantgen M, Von Rueden K, Greenspan JD, Dorsey SG, Renn CL.

Pain Manag Nurs. 2016 Feb;17(1):3-13. doi: 10.1016/j.pmn.2015.06.010. Epub 2015 Nov 3.

24.

LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application.

Pont MJ, Hobo W, Honders MW, van Luxemburg-Heijs SA, Kester MG, van Oeveren-Rietdijk AM, Schaap N, de Boer HC, van Bergen CA, Dolstra H, Falkenburg JH, Griffioen M.

Haematologica. 2015 Oct;100(10):e419-22. doi: 10.3324/haematol.2015.125021. Epub 2015 Jun 11. No abstract available.

25.

Evaluation of dynamic weight bearing for measuring nonevoked inflammatory hyperalgesia in mice.

Griffioen MA, Dernetz VH, Yang GS, Griffith KA, Dorsey SG, Renn CL.

Nurs Res. 2015 Mar-Apr;64(2):81-7. doi: 10.1097/NNR.0000000000000082.

26.

Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.

Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH, van Bergen CA, Griffioen M, Falkenburg JH, van Veelen PA, Heemskerk MH.

Clin Cancer Res. 2015 May 1;21(9):2177-86. doi: 10.1158/1078-0432.CCR-14-2188. Epub 2015 Jan 14.

27.

Gender differences in immediate hypersensitivity reactions to vaccines: a review of the literature.

Griffioen M, Halsey N.

Public Health Nurs. 2014 May-Jun;31(3):206-14. doi: 10.1111/phn.12073. Epub 2013 Aug 5. Review.

PMID:
24720655
28.

Human leukocyte antigen-DO regulates surface presentation of human leukocyte antigen class II-restricted antigens on B cell malignancies.

Kremer AN, van der Meijden ED, Honders MW, Pont MJ, Goeman JJ, Falkenburg JH, Griffioen M.

Biol Blood Marrow Transplant. 2014 May;20(5):742-7. doi: 10.1016/j.bbmt.2014.02.005. Epub 2014 Feb 14.

29.

Durable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception?

van Bergen CA, Verdegaal EM, Honders MW, Hoogstraten C, Steijn-van Tol AQ, de Quartel L, de Jong J, Meyering M, Falkenburg JH, Griffioen M, Osanto S.

PLoS One. 2014 Jan 15;9(1):e85198. doi: 10.1371/journal.pone.0085198. eCollection 2014.

30.

Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.

Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, Jones JF, LaRussa PS, Garner J, Berger M, Proveaux T, Vellozzi C; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment Network, Broder K, Setse R, Pahud B, Hrncir D, Choi H, Sparks R, Williams SE, Engler RJ, Gidudu J, Baxter R, Klein N, Edwards K, Cano M, Kelso JM.

Vaccine. 2013 Dec 9;31(51):6107-12. doi: 10.1016/j.vaccine.2013.09.066. Epub 2013 Oct 8.

PMID:
24120547
31.

Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.

Kremer AN, van der Griendt JC, van der Meijden ED, Honders MW, Ayoglu B, Schwenk JM, Nilsson P, Falkenburg JH, Griffioen M.

Haematologica. 2014 Feb;99(2):365-9. doi: 10.3324/haematol.2013.086652. Epub 2013 Oct 4.

32.

HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.

Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, van de Meent M, Harskamp JC, Claas FH, Marijt EW, Zwaginga JJ, Halkes CJ, Jedema I, Griffioen M, Falkenburg JH.

Blood. 2013 Sep 12;122(11):1963-73. doi: 10.1182/blood-2012-12-470872. Epub 2013 Jun 18.

33.

Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.

Stevanović S, Nijmeijer BA, van Schie ML, Salvatori DC, Maas S, Griffioen M, Falkenburg JH.

Biol Blood Marrow Transplant. 2013 Jun;19(6):867-75. doi: 10.1016/j.bbmt.2013.03.003. Epub 2013 Mar 13.

34.

Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice.

Unger WW, Pearson T, Abreu JR, Laban S, van der Slik AR, der Kracht SM, Kester MG, Serreze DV, Shultz LD, Griffioen M, Drijfhout JW, Greiner DL, Roep BO.

PLoS One. 2012;7(11):e49213. doi: 10.1371/journal.pone.0049213. Epub 2012 Nov 14.

35.

Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP, Griffioen M, Spierings E, Lokhorst HM, Mutis T.

Leukemia. 2013 Mar;27(3):642-9. doi: 10.1038/leu.2012.277. Epub 2012 Oct 1.

36.

HLA-class II disparity is necessary for effective T cell mediated Graft-versus-Leukemia effects in NOD/scid mice engrafted with human acute lymphoblastic leukemia.

Stevanović S, van Schie ML, Griffioen M, Falkenburg JH.

Leukemia. 2013 Apr;27(4):985-7. doi: 10.1038/leu.2012.270. Epub 2012 Sep 17. No abstract available.

PMID:
22982971
37.

Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.

Kremer AN, van der Meijden ED, Honders MW, Goeman JJ, Wiertz EJ, Falkenburg JH, Griffioen M.

Blood. 2012 Oct 18;120(16):3246-55. doi: 10.1182/blood-2011-12-399311. Epub 2012 Aug 13.

38.

Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.

Rutten CE, van Luxemburg-Heijs SA, Halkes CJ, van Bergen CA, Marijt EW, Oudshoorn M, Griffioen M, Falkenburg JH.

Biol Blood Marrow Transplant. 2013 Jan;19(1):40-8. doi: 10.1016/j.bbmt.2012.07.020. Epub 2012 Aug 4.

39.

Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.

Griffioen M, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Lurvink EG, Kester MG, van Bergen CA, Falkenburg JH.

Haematologica. 2012 Aug;97(8):1196-204. doi: 10.3324/haematol.2011.049478. Epub 2012 Mar 14.

40.

Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.

Zandvliet ML, Kester MG, van Liempt E, de Ru AH, van Veelen PA, Griffioen M, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2012 Feb-Mar;35(2):142-53. doi: 10.1097/CJI.0b013e318243f1ed.

PMID:
22306902
41.

Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.

Stevanović S, Griffioen M, Nijmeijer BA, van Schie ML, Stumpf AN, Rutten CE, Willemze R, Falkenburg JH.

Leukemia. 2012 Feb;26(2):312-22. doi: 10.1038/leu.2011.222. Epub 2011 Aug 23.

PMID:
21860431
42.

PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer.

Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, de Ru AH, Lugthart GJ, van Kooten C, Hiemstra PS, Jedema I, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Clin Cancer Res. 2011 Sep 1;17(17):5615-25. doi: 10.1158/1078-0432.CCR-11-1066. Epub 2011 Jul 19.

43.

A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR.

Broen K, Levenga H, Vos J, van Bergen K, Fredrix H, Greupink-Draaisma A, Kester M, Falkenburg JH, de Mulder P, de Witte T, Griffioen M, Dolstra H.

PLoS One. 2011;6(6):e21699. doi: 10.1371/journal.pone.0021699. Epub 2011 Jun 28.

44.

High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.

Van Bergen CA, Rutten CE, Van Der Meijden ED, Van Luxemburg-Heijs SA, Lurvink EG, Houwing-Duistermaat JJ, Kester MG, Mulder A, Willemze R, Falkenburg JH, Griffioen M.

Cancer Res. 2010 Nov 15;70(22):9073-83. doi: 10.1158/0008-5472.CAN-10-1832. Epub 2010 Nov 9.

45.

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.

Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH.

Blood. 2010 Dec 23;116(26):5930-40. doi: 10.1182/blood-2010-01-262006. Epub 2010 Sep 15.

46.

HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1-specific CD4+ T cell responses showing immunogenicity of all HLA-DPB1 alleles.

Rutten CE, van Luxemburg-Heijs SA, van der Meijden ED, Griffioen M, Oudshoorn M, Willemze R, Falkenburg JH.

Biol Blood Marrow Transplant. 2010 Sep;16(9):1282-92. doi: 10.1016/j.bbmt.2010.03.018. Epub 2010 Mar 27.

47.

Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro.

Rutten CE, van Luxemburg-Heijs SA, van der Meijden ED, Griffioen M, Oudshoorn M, Willemze R, Falkenburg JH.

Blood. 2010 Jan 7;115(1):151-3. doi: 10.1182/blood-2009-10-249821. No abstract available.

48.

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy.

Griffioen M, van Egmond EH, Kester MG, Willemze R, Falkenburg JH, Heemskerk MH.

Haematologica. 2009 Sep;94(9):1316-20. doi: 10.3324/haematol.2008.001677.

49.

Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.

Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M.

Blood. 2009 Oct 22;114(17):3684-92. doi: 10.1182/blood-2009-03-208017. Epub 2009 Aug 25.

50.

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application.

Griffioen M, van Egmond HM, Barnby-Porritt H, van der Hoorn MA, Hagedoorn RS, Kester MG, Schwabe N, Willemze R, Falkenburg JH, Heemskerk MH.

Haematologica. 2008 Oct;93(10):1535-43. doi: 10.3324/haematol.13067. Epub 2008 Sep 2.

Supplemental Content

Loading ...
Support Center